ICU sedation, delirium & recovery
Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial
- stopped early (COVID-19 pandemic)
- Stopped early after the COVID-19 pandemic
Authors' conclusion
Our findings in this rather small study signal a possible positive effect of minocycline on delirium incidence.
Study context
- Population
- Critically ill adults (≥18 years) in 4 ICUs159 analysed
- Participants
- 160 adults
- Comparison
- Minocycline 100 mg twice daily vs placebo
- Minocyclinen = 84
- Placebon = 75reference
- Primary endpoint
- Delirium incidence
- Follow-up
- Within 28 days or before ICU discharge
Methodological detailsplacebo-controlled, double-anonymized, multicentre (4 ICUs)
- Placebo-controlled
- Double-anonymized
- Multicentre (4 ICUs)
Primary result
As reported in the abstract
P = 0.043
Secondary outcomes
Other delirium-related outcomes
- No other delirium-related outcomes modified by minocycline
Hospital mortality
- Significant decrease in hospital mortality (39% vs. 23%)
- P = 0.029
- Unexpected finding
C-reactive protein plasma levels (exploratory)
- Only biomarker to decrease significantly after minocycline; within time
- F = 0.75, P = .78
- Group × time
- F = 4.09, P = .045
Original publication
Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial. Chest. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →